Gilead Sciences has announced that the FDA has approved Zydelig (idelalisib) in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy, as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.

Zydelig is a first-in-class oral inhibitor of PI3K delta, a protein which plays a role in the activation, proliferation, and viability of B cells.

RELATED: Low-Volume, Short Infusion Time Tx Designated Orphan Drug for Hematological Cancers

Zydelig will be available in 100mg and 150mg strength tablets.

For more information call (800) 445-3235 or visit